PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology
- PMID: 9089436
- DOI: 10.1023/a:1008094712424
PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology
Abstract
This paper describes a novel methodology, PRO_SELECT, which combines elements of structure-based drug design and combinatorial chemistry to create a new paradigm for accelerated lead discovery. Starting with a synthetically accessible template positioned in the active site of the target of interest, PRO_SELECT employs database searching to generate lists of potential substituents for each substituent position on the template. These substituents are selected on the basis of their being able to couple to the template using known synthetic routes and their possession of the correct functionality to interact with specified residues in the active site. The lists of potential substituents are then screened computationally against the active site using rapid algorithms. An empirical scoring function, correlated to binding free energy, is used to rank the substituents at each position. The highest scoring substituents at each position can then be examined using a variety of techniques and a final selection is made. Combinatorial enumeration of the final lists generates a library of synthetically accessible molecules, which may then be prioritized for synthesis and assay. The results obtained using PRO_SELECT to design thrombin inhibitors are briefly discussed.
Similar articles
-
Active-site-directed 3D database searching: pharmacophore extraction and validation of hits.J Comput Aided Mol Des. 1996 Oct;10(5):397-416. doi: 10.1007/BF00124472. J Comput Aided Mol Des. 1996. PMID: 8951650
-
Computational combinatorial ligand design: application to human alpha-thrombin.J Comput Aided Mol Des. 1996 Oct;10(5):372-96. doi: 10.1007/BF00124471. J Comput Aided Mol Des. 1996. PMID: 8951649
-
Templates for design of inhibitors for serine proteases: application of the program DOCK to the discovery of novel inhibitors for thrombin.Bioorg Med Chem Lett. 1998 Sep 22;8(18):2463-6. doi: 10.1016/s0960-894x(98)00444-2. Bioorg Med Chem Lett. 1998. PMID: 9873562
-
Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery.Structure. 1997 Mar 15;5(3):319-24. doi: 10.1016/s0969-2126(97)00189-5. Structure. 1997. PMID: 9083110 Review.
-
De novo drug design.Methods Mol Biol. 2011;672:299-323. doi: 10.1007/978-1-60761-839-3_12. Methods Mol Biol. 2011. PMID: 20838974 Review.
Cited by
-
Fragment oriented molecular shapes.J Mol Graph Model. 2016 May;66:143-54. doi: 10.1016/j.jmgm.2016.03.017. Epub 2016 Apr 2. J Mol Graph Model. 2016. PMID: 27085751 Free PMC article.
-
A very large diversity space of synthetically accessible compounds for use with drug design programs.J Comput Aided Mol Des. 2005 Jan;19(1):47-63. doi: 10.1007/s10822-005-0097-6. J Comput Aided Mol Des. 2005. PMID: 16059666
-
Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.J Comput Aided Mol Des. 1997 Sep;11(5):425-45. doi: 10.1023/a:1007996124545. J Comput Aided Mol Des. 1997. PMID: 9385547
-
Docking, virtual high throughput screening and in silico fragment-based drug design.J Cell Mol Med. 2009 Feb;13(2):238-48. doi: 10.1111/j.1582-4934.2008.00665.x. Epub 2009 Jan 21. J Cell Mol Med. 2009. PMID: 19183238 Free PMC article. Review.
-
Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.J Mol Model. 2019 May 25;25(6):171. doi: 10.1007/s00894-019-4032-5. J Mol Model. 2019. PMID: 31129879
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources